Navigation Links
VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
Date:2/11/2008

n biotechnologies, inc. is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven, which is based in South San Francisco, California, has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. Please visit http://www.ravenbio.com for more information about Raven biotechnologies inc.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include, without limitation, VaxGen's and Raven's ability to meet the conditions necessary to close the proposed merger between the two companies, the benefits of the proposed merger, the ability to meet the stated drug development and financial objectives of the merged company, and the ability to and timing to successfully integrate Raven and VaxGen following consummation of the merger. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Additional information concerning these and other risk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2006 and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen and Raven undertake no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Additional Information and Where to Find It

VaxGen has filed a registration statement on Form
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. VaxGen Addresses MPM Claims in Letter to Stockholders
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
10. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
11. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... solutions, today announced its GHS Label Guide . To align chemical container ... (GHS), this guide includes explanations of label components, an example of an accurate ...
(Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
(Date:7/29/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... pleased to announce that the final design specifications ... locked.  Prototypes for industrial and regulatory testing will ... for CE mark clearance to market the injector ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Brady Announces a New GHS Label Guide 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... 28 , - New ... , Bial-Portela & CA, S.A., ... Portela), and Eisai Europe Limited (London; Chairman & CEO ... President &,CEO: Haruo Naito), today announced that the novel ...
... scientists have unlocked the physics of the perfect pizza ... generation of micro motors thinner that a human hair. ... by Associate Professor James Friend and Senior Lecturer Leslie ... team from Monash,s Micro/Nanophysics Research Laboratory, then calculated how ...
... -- Encorium Group, Inc. (Nasdaq: ... (CRO) that provides design, development, and management capabilities ... of the world,s leading pharmaceutical companies, today announced ... Annual Vaccine Industry Excellence Award for Best Contract ...
Cached Biology Technology:Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 2Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 3Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 4Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 5Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 6Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 7Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 8Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 9Pizza tossing art unlocks secrets of tiny motors 2Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 2Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 3Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 4
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... established HPV types. Cancerous human papillomavirus (HPV) viruses are the ... to 100% of cervical tumors. Cervical cancer and ... virus using standard techniques can sometimes give a negative result ... In a new study published in Virology , ...
... critically endangered large primate known as the drill ( ... few critical habitat areas in Cameroon, according to a ... Zoo,s Institute for Conservation Research. The study highlights ... area becomes ever more fragmented by human disturbance. ...
... infectious diseases meeting of the American Society for Microbiology ... Antimicrobial Agents and Chemotherapy (ICAAC) will be held September ... Colorado. Known as the preeminent world meeting for ... infectious diseases and anti-infective therapy, ICAAC has also traditionally ...
Cached Biology News:53rd ICAAC: Media registration now open 2
... for RNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... DNA/RNA Aptamer Microarray Service. Probe ... Microarray contains greater than 1500 known aptamer ...
... RNA aptamer screening and binding optimization and ... microfluidic on-chip synthesis platform. Thousands of customer ... and LC Sciences can provide assistance with ... as part of our comprehensive DNA/RNA Aptamer ...
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... from the C-terminal end of the mouse retinoic acid receptor beta (RAR*). ... 448 of RAR*. The sequence of PEP-005 is (amino to carboxy ... - S - S - V - E - N - S ... - L - L - Q (The N-terminal cysteine has been ...
Biology Products: